The largest database of trusted experimental protocols
> Disorders > Disease or Syndrome > Left-Sided Heart Failure

Left-Sided Heart Failure

Left-Sided Heart Failure: Discover how PubCompare.ai, an AI-driven platform, can help you optimize your research protocols for this condition.
Locate and compare protocols from literature, preprints, and patents to identify the best approaches.
Our AI-powered comparisons unlock insights to streamline your research and find the most effective solutions for managing left-sided heart failure, a common and serious condition where the left side of the heart is unable to pump blood effectively.

Most cited protocols related to «Left-Sided Heart Failure»

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Acute Lung Injury Atelectasis Brain Death Cryopreservation Disease, Chronic Donor, Organ Donors Hepatitis B Homo sapiens Left-Sided Heart Failure Lung Malignant Neoplasms Organ Procurement Radiography, Thoracic Respiratory Distress Syndrome, Adult Tissues Transplantation
Echocardiography and hemodynamic measurements were performed at the indicated times after the mice were anesthetized using 1.5–2% isoflurane3 (link)5 (link)6 (link)22 (link)37 (link)44 (link)45 (link). For echocardiography, M-mode images derived from the short axis of the LV were recorded using a Mylab30CV (ESAOTE) machine with a 15-MHz probe. To measure the LVEDD, LVESD and LVFS (LVFS (%)=(LVEDD-LVESD)/LVEDD × 100%), M-mode measurements of the LV internal diameter were obtained from at least three beats and then averaged. Cardiac catheterization studies were performed using a 1.4-French Millar catheter-tip micromanometer catheter (SPR-839; Millar Instruments), which was inserted through the right carotid artery into the left ventricle. The pressure and dp/dt were recorded continuously with an Aria pressure-volume conductance system coupled to a Powerlab/4SP A/D converter and were stored and displayed on a personal computer.
Publication 2014
Catheterizations, Cardiac Catheters Common Carotid Artery Echocardiography Epistropheus Hemodynamics Left-Sided Heart Failure Left Ventricles Mus NRG1 protein, human Pressure

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2010
Catheters Chloride, Cadmium Diastole Echocardiography Gene Expression Heart Immunohistochemistry Left-Sided Heart Failure Left Ventricles Microspheres Mus Myocardium paraform Perfusion Transducers Ventricular Ejection Fraction
We included all patients who underwent coronary angiography with the primary indication of HF corresponding to International Classification of Diseases (ICD) 10th revision codes I50.1 (left ventricular failure), I50.2 [systolic (congestive) HF], I50.4 [combined systolic (congestive) and diastolic (congestive) HF], or I50.9 (HF, unspecified) and that showed concomitant MVD (coronary artery stenosis >50% in ≥2 vessels or left main) between 1 January 2000 and 31 March 2018. No patient was hospitalized for acute coronary syndrome (i.e. ST-elevation or non-ST-elevation myocardial infarction) within the 6 months before the index coronary angiography. All patients were included in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) and Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions (RIKS-HIA), which are part of the Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies (SWEDEHEART) registry and was established in 1992. Swedish Coronary Angiography and Angioplasty Registry provides a web-based platform dedicated to data collection from all angiographies and PCIs performed in coronary catheterization laboratories (n = 31) in Sweden (https://www.ucr.uu.se/swedeheart/). Each catheterization procedure is described with ∼50 angiographic and 200 PCI, demographic- and procedure-related variables. The registry is financed by the county councils in Sweden and the Swedish state and provides ∼100% procedure coverage in Sweden. To obtain information about vital status of the patients, the SCAAR database is continuously merged with the national population registry. More detailed information about SCAAR’s organization has been published elsewhere.10–14 (link) The study was approved by the ethics committee at the University of Gothenburg (Dnr. 759-13, date of approval 6 May 2014).
Publication 2021
Acute Coronary Syndrome Angiography Angioplasty Angioplasty, Balloon, Coronary Blood Vessel Catheterization Catheterizations, Cardiac Coronary Angiography Coronary Stenosis Diastole Ethics Committees Heart Heart Diseases Intensive Care Left-Sided Heart Failure Non-ST Elevated Myocardial Infarction Patients Systole
Client‐owned dogs that were clinically healthy or had MMVD were prospectively included in our study. Dogs were diagnosed as clinically healthy based on medical history, physical examination, electrocardiography, radiography, noninvasive blood pressure measurement, and transthoracic echocardiography. Dogs were diagnosed as having MMVD based on the presence of mitral valve thickening or prolapse and mitral regurgitation, as identified using transthoracic echocardiography.25 If dogs with MMVD also had tricuspid regurgitation (TR), they were deemed as having PH according to TR ≥3.0 m/s (TR pressure gradient [TRPG] ≥36 mmHg). Dogs that had other cardiac diseases, diseases that might affect the cardiac function or pulmonary artery pressure (eg, respiratory disease, thromboembolic disease, heartworm disease, neoplastic disease, endocrine disease), and systemic hypertension (systolic blood pressure ≥160 mmHg)26 were excluded from the study along with cases that had missing data.
Dogs with MMVD were divided into 3 groups based on the American College of Veterinary Internal Medicine consensus: stage B1 consisted of asymptomatic dogs with no or minimal remodeling, stage B2 consisted of asymptomatic dogs with substantial remodeling based on radiography and echocardiography, and stage C/D consisted of symptomatic dogs with current or past clinical signs of heart failure caused by MMVD.27 In addition, dogs with MMVD were classified into 4 groups based on TRPG: non‐PH, defined as TRPG <36 mmHg or absence of TR; mild PH, defined as TRPG of 36 to 50 mmHg; moderate PH, defined as TRPG of 50 to 75 mmHg; and severe PH, defined as TRPG >75 mmHg.5, 12 Furthermore, dogs with TR were classified qualitatively according to TR severity using color Doppler and continuous wave Doppler methods: mild TR consisted of dogs with a small TR jet based on color Doppler and a faint parabolic TR jet signal based on the continuous wave Doppler; moderate TR consisted of those with an intermediate TR jet and a dense parabolic TR jet signal; and severe TR consisted of those with a substantial large central or eccentric wall‐impinging TR jet and a dense triangular, early‐peaking TR jet signal.28, 29 Dogs were diagnosed as having left‐sided congestive heart failure if they had at least 1 clinical sign, such as tachypnea, respiratory distress, or exercise intolerance, supported by radiographic and ultrasonographic evidence of pulmonary venous congestion and pulmonary edema. Dogs were diagnosed as having R‐CHF if they had at least 1 radiographic and ultrasonographic finding indicative of ascites, pleural effusion or pericardial effusion or clinical signs of cardiac syncope, jugular venous congestion, or peripheral edema without any evidence of diseases except for PH, other than neurological diseases.
Publication 2020
Ascites Canis familiaris Determination, Blood Pressure Dirofilariasis Echocardiography Edema Effusion, Pericardial Electrocardiography Endocrine System Diseases Heart Heart Diseases Heart Failure High Blood Pressures Left-Sided Heart Failure Mitral Valve Mitral Valve Insufficiency Neoplasms Nervous System Disorder Physical Examination Pleural Effusion Pressure Prolapse Pulmonary Artery Pulmonary Edema Respiration Disorders Respiratory Rate Syncope Syncope, Cardiogenic Systolic Pressure Thromboembolism Tricuspid Valve Insufficiency Veins, Pulmonary Venous Engorgement X-Rays, Diagnostic

Most recents protocols related to «Left-Sided Heart Failure»

Left ventricular function in mice was assessed using echocardiography (Philips TIS 0.8; Koninklijke Philips N.V.) and an RMV 707B transducer (frequency, 30 MHz; Siemens AG). The mice were anesthetized with isoflurane (dose for both induction and maintenance, 2%) before echocardiography. Images were obtained by identifying the interventricular septum and the left ventricular posterior wall. The left ventricular fractional shortening (LVFS; %) and left ventricular ejection fraction (LVEF; %) were automatically calculated by echocardiography. Each parameter was evaluated by calculating the average of four cardiac cycles. All mice in the present study were sacrificed by cervical dislocation at the end of this experiment.
Publication 2023
Echocardiography Heart Isoflurane Joint Dislocations Left-Sided Heart Failure Left Ventricles Left Ventricular Function Mice, Laboratory Neck Transducers Ventricular Ejection Fraction Ventricular Septum
Both devices configurations were individually and consecutively tested on the same testing loop (Figure 1). The conditions for the study were simulated by using a test loop specifically configured for biventricular testing (15 (link)), which has been used previously for characterization of other CF devices and disease states. The test loop has two pneumatic pumps (Abiomed AB5000, Danvers, MA, USA) powered from a dual-output driver (Figure 2). The working fluid in the test loop was a blood analog glycerin/water mixture with a specific gravity of 1.060. Manual valves simulated vascular resistances, closed pneumatic reservoirs created arterial compliances, and pump inlets were filled by open reservoirs. Inflows for both BVADs were connected to the loop in both ventricular and atrial positions. Adjustable parameters for the loop included: fluid volumes, drive pressures, beat rates for pumps, loop compliance, vascular resistance (systemic and pulmonary), and shunt flows between all four chambers. For this study, we varied the drive pressures to simulate four different conditions: moderate left heart failure (LHF), moderate right heart failure (RHF), moderate biventricular failure (BHF), and severe BHF (Table 1).
Full text: Click here
Publication 2023
A-A-1 antibiotic Arteries BLOOD Glycerin Heart Atrium Heart Failure Heart Ventricle Left-Sided Heart Failure Lung Medical Devices Vascular Resistance
Our primary outcome of interest was death attributable to COVID-19. We defined COVID-19 attributable deaths as those coded as U07.1 or U07.2 in ONS data. In a sensitivity analysis we explored broadening our primary outcome of death attributable to COVID-19 to all-cause death which occurred within 28 days of the individual's diagnosis (based on test result among those with laboratory-confirmed SARS-CoV-2 or consultation date for those with clinically reported COVID-19). Our secondary outcomes were hospitalisation due to COVID-19 (defined by COVID-19 in the primary diagnosis field of any episode recorded in HES APC or presence in CHESS dataset), ICU admission due to COVID-19 (defined by ICU admission recorded in CHESS), need for respiratory support due to COVID-19 (defined by mechanical ventilation recorded in CHESS), or major adverse cardiovascular event (MACE [composite of acute coronary syndrome which included myocardial infarction and unstable angina, ischaemic stroke, acute left ventricular failure, or major ventricular arrhythmia recorded in CPRD or HES APC]). These definitions were informed by a systematic review of the validity of cardiovascular event recording in electronic health records.19 (link)
Full text: Click here
Publication 2023
Acute Coronary Syndrome Angina, Unstable Cardiac Arrhythmia Cardiovascular System COVID 19 Diagnosis Heart Ventricle Hypersensitivity Left-Sided Heart Failure Mechanical Ventilation Myocardial Infarction Myristica fragrans Respiratory Rate SARS-CoV-2 Stroke, Ischemic
Transthoracic echocardiography was performed at baseline (before experiments) and after reperfusion in anesthetized rats using a Visual Sonic Vevo2100 system with an MS-250 transducer. Heart rate and left ventricular (LV) parameters, including diastolic and systolic wall thickness, LV end-diastolic and end-systolic diameters, and LV functional parameters, including left ventricular ejection fraction (LVEF) and LV fractional shortening (LVFS), LV end-systolic interior diameter (LVID.s), end-diastolic interior diameter (LVID. d), were measured from a 2D short axis at the papillary muscle level in M-mode images using Vevo 2,100 software.
Full text: Click here
Publication 2023
Diastole Echocardiography Epistropheus Left-Sided Heart Failure Left Ventricles Papillary Muscles Rate, Heart Rattus norvegicus Reperfusion Systole Transducers Ventricular Ejection Fraction
The current analysis is an observational, retrospective cohort study conducted at a single location between October 2013 and February 2017 on patients with ACS who underwent emergency PCI with DES at the First Affiliated Hospital of Xi'an Jiaotong University, Yanta. The inclusion criteria of the current analysis are as follows: (1) patients between the age of 18 and 80 years; (2) patients with ACS who received DAPT for 12–24 months and who had no clinical ischemic or bleeding events during the first 12 months; and (3) patients who successfully underwent emergency PCI with DES. A total of 3,236 patients with ACS were investigated. The exclusion criteria for this study are as follows: (1) a history of coronary artery bypass grafting, cardiogenic shock, malignant tumor, significant infection, or autoimmune disease; (2) a renal disorder with an estimated glomerular filtration rate (eGFR) of < 30 mL/min/1.73 m2) or accepted renal replacement treatment; (3) hepatic dysfunction with aspartate transaminase or alanine transaminase levels greater than five upper limits of normal; (4) non-obstructive coronary disease, primary cardiomyopathy, and valvular heart disease; (5) heart failure with left ventricular ejection fraction (LVEF) <30%; (6) oral anticoagulants during follow-up; (7) anemia with hemoglobin (Hb) <60 g/L; (8) a history of gastrointestinal bleeding and hemorrhagic stroke; and (9) missing clinical data. A total of 987 patients were excluded following the exclusion criteria. Finally, 2,249 patients were included in the group. If DAPT was continued for 12 or 12–24 months, it was classified as the standard (n = 1,011) or prolonged (n = 1,238) DAPT group. The duration of the prolonged DAPT group is 22 (20, 24) months (Figure 1).
Full text: Click here
Publication 2023
1,2-dilinolenoyl-3-(4-aminobutyryl)propane-1,2,3-triol Alanine Transaminase Anemia Anticoagulants Autoimmune Diseases Cardiomyopathies, Primary Coronary Artery Disease Emergencies Glomerular Filtration Rate Hemoglobin Hemorrhagic Stroke Infection Kidney Kidney Diseases Left-Sided Heart Failure Malignant Neoplasms Patients Shock, Cardiogenic Transaminase, Serum Glutamic-Oxaloacetic Valve Disease, Heart Ventricular Ejection Fraction

Top products related to «Left-Sided Heart Failure»

Sourced in Canada, United States, Japan
The Vevo 2100 is a high-resolution, real-time in vivo imaging system designed for preclinical research. It utilizes advanced ultrasound technology to capture detailed images and data of small animal subjects.
Sourced in Canada, United States, Japan
The Vevo 770 is a high-resolution, real-time, in vivo micro-imaging system designed for small animal research. It employs high-frequency ultrasound technology to produce detailed anatomical and functional images.
Sourced in Canada, United States
The Vevo 2100 Imaging System is a high-resolution ultrasound platform designed for preclinical research applications. It provides real-time, high-quality imaging of small animals and other biological samples.
Sourced in Canada, United States
The Vevo 2100 system is a high-frequency, high-resolution micro-ultrasound imaging platform designed for preclinical research applications. The system utilizes advanced transducer technology to capture real-time, high-quality images and data from small animal models.
Sourced in Canada
The Vevo 770 imaging system is a high-resolution, real-time, in vivo micro-imaging platform designed for preclinical research. It provides a versatile imaging solution for a variety of applications, including small animal studies.
Sourced in Canada
The 30-MHz transducer is a type of lab equipment designed for specialized applications. It operates at a frequency of 30 megahertz, which is a technical specification. The core function of this transducer is to generate and detect ultrasonic waves, but a detailed description of its intended use is not available.
Sourced in Canada, United States, Japan
The Vevo 3100 is a high-resolution, real-time micro-imaging system designed for preclinical research. It is capable of producing high-quality images of small animals and other biological samples using ultrasound technology.
Sourced in Japan, China
The BP-98A is a laboratory instrument designed for measuring blood pressure. It provides accurate readings of systolic and diastolic blood pressure values.
Sourced in Canada, United States, Japan
The Vevo 2100 ultrasound system is a lab equipment product designed for high-resolution imaging of small animals and other research applications. It utilizes advanced ultrasound technology to capture real-time, high-quality images and data.
Sourced in Japan
The Xario SSA-660A is a medical ultrasound system manufactured by Toshiba. It is designed to provide high-quality imaging for a variety of clinical applications. The core function of the Xario SSA-660A is to capture and display real-time images of the body's internal structures using ultrasound technology.

More about "Left-Sided Heart Failure"

Left-Sided Heart Failure (LSHF) is a common and serious cardiovascular condition where the left side of the heart is unable to pump blood effectively.
This can lead to a buildup of fluid in the lungs and other parts of the body, causing symptoms like shortness of breath, fatigue, and swelling.
LSHF can be caused by a variety of underlying conditions, such as coronary artery disease, high blood pressure, or cardiomyopathy.
Accurate diagnosis and monitoring of LSHF is crucial for effective management and treatment.
Imaging technologies like the Vevo 2100, Vevo 770, and Vevo 3100 ultrasound systems can be particularly helpful in assessing cardiac function and guiding treatment decisions.
These systems, equipped with high-frequency transducers like the 30-MHz transducer, provide detailed, real-time images of the heart's structure and performance.
To optimize research protocols for LSHF, the AI-driven platform PubCompare.ai can be a valuable tool.
By locating and comparing protocols from literature, preprints, and patents, PubCompare.ai can help researchers identify the most effective approaches for managing this condition.
Its AI-powered comparisons unlock insights that can streamline research and lead to more effective solutions for LSHF patients.
Whether you're a clinician, researcher, or healthcare professional, understanding the latest advancements in LSHF diagnosis and treatment, as well as the tools available to support your work, can be crucial for delivering the best possible care to patients.
By staying up-to-date on the latest developments in this field, you can ensure that your research and clinical practices are optimized for the management of this common and serious cardiovascular condition.